Systematic review of the use of translated patient-reported outcome measures in cancer trials

被引：0
作者：
A. L. Slade
A. Retzer
K. Ahmed
D. Kyte
T. Keeley
J. Armes
J. M. Brown
L. Calman
A. Gavin
A. W. Glaser
D. M. Greenfield
A. Lanceley
R. M. Taylor
G. Velikova
G. Turner
M. J. Calvert
机构：
[1] University of Birmingham,Centre for Patient Reported Outcomes Research, Institute of Applied Health Research
[2] University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham,National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre
[3] University of Birmingham,National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre
[4] University of Birmingham,Birmingham Clinical Trials Unit
[5] National Cancer Research Institute (NCRI) Psychosocial Oncology and Survivorship Clinical Studies Group subgroup: Understanding and measuring the consequences of cancer and its treatment,Patient Centred Outcomes
[6] GlaxoSmithKline,School of Health Sciences
[7] University of Surrey,Clinical Trials Research Unit
[8] NIHR Applied Research Collaboration Kent Surrey & Sussex University of Surrey,Macmillan Survivorship Research Group, Health Sciences
[9] University of Leeds,Northern Ireland Cancer Registry, Centre for Public Health
[10] University of Southampton,Leeds Institute of Medical Research at St James’s
[11] Queens University Belfast,Elizabeth Garrett Anderson Institute for Women’s Health
[12] University of Leeds,Cancer Clinical Trials Unit
[13] Sheffield Teaching Hospital NHS Foundation Trust,National Institute for Health Research Applied Research Collaboration
[14] University College London,Birmingham Health Partners Centre for Regulatory Science and Innovation
[15] University College London Hospitals NHS Foundation Trust,undefined
[16] University of Birmingham,undefined
[17] University of Birmingham,undefined
来源：
Trials | / 22卷
关键词：
Patient-reported outcomes (PROs), Patient-reported outcome measures (PROMs), Ethnicity, Recruitment, Cross-cultural translation, Clinical trials, Trial protocols, Primary outcomes, Secondary outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 393 条
  • [1] Mercieca-Bebber R(2017)Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension Qual Life Res 26 1427-1437
  • [2] Rouette J(2009)Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report Value Health 12 430-440
  • [3] Calvert M(2006)Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study Lancet Oncol 7 903-909
  • [4] Wild D(2013)Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) Health Serv Insights 6 61-68
  • [5] Eremenco S(2013)Reporting of patient reported outcomes in randomised trials: the CONSORT PRO extension JAMA. 309 814-822
  • [6] Mear I(2012)The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy Med Care 50 1060-1070
  • [7] Martin M(2018)Patient led PROMs must take centre stage in cancer research Res Involve Engage 4 7-988
  • [8] Houchin C(2015)Assessment of patient-reported adverse events after discharge from hospital in RCTs in gastrointestinal cancer surgery: is there sufficient coverage in existing EORTC questionnaires? Trials. 16 48-977
  • [9] Gawlicki M(2011)Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2—assessing respondent understanding Value Health 14 978-104
  • [10] Hareendran A(2014)Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 Value in Health 14 967-1178
12345678910